When to Increase Tirzepatide Dose: The Clinical Decision Framework for Safe Escalation

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The standard escalation interval is 4 weeks at each dose, matching the protocol from SURMOUNT-1 and manufacturer guidelines, not an arbitrary waiting period
• Increase only if side effects are mild or absent AND weight loss has plateaued for 2+ consecutive weeks at the current dose
• Stay at your current dose longer if you experience moderate nausea, vomiting more than twice weekly, or persistent fatigue that interferes with daily function
• The maximum recommended dose is 15 mg weekly, though clinical response often plateaus between 10 mg and 12.5 mg for most patients

Direct answer (40-60 words)

Increase your tirzepatide dose after 4 weeks at the current level if you tolerate it well (minimal nausea, no vomiting) and weight loss has stalled for at least 2 weeks. Skip the increase if you're still experiencing moderate side effects or losing 1+ pounds weekly. The decision prioritizes tolerance over speed.

Table of contents

1. The 4-week escalation rule and why it exists
2. The FormBlends Dose Escalation Decision Tree
3. What "tolerating well" actually means in clinical terms
4. When weight loss plateau justifies an increase
5. The three scenarios where you should NOT increase dose
6. What most articles get wrong about "listening to your body"
7. Dose-by-dose escalation timeline: 2.5 mg to 15 mg
8. Side effect severity scale: mild vs. moderate vs. severe
9. The case for staying at a lower dose permanently
10. How compounded tirzepatide changes the escalation calculus
11. When to contact your provider before escalating
12. FAQ

The 4-week escalation rule and why it exists

The standard tirzepatide titration protocol increases the dose every 4 weeks. This isn't a suggestion. It's the interval tested in every major clinical trial (SURMOUNT-1, SURMOUNT-2, SURMOUNT-3, SURMOUNT-4) and embedded in the FDA-approved prescribing information for Mounjaro and Zepbound.

The 4-week minimum exists because tirzepatide takes 4 to 5 weeks to reach steady-state plasma concentration. Steady state is the point where the amount of drug entering your system each week equals the amount being eliminated. Before steady state, you're still ramping up. Side effects can emerge or intensify during weeks 2 and 3 at a new dose, then resolve by week 4 as your GI tract adapts.

Escalating before 4 weeks means stacking a new dose increase on top of a body still adjusting to the previous one. The result is compounded nausea, a higher risk of vomiting and dehydration, and more treatment discontinuations. A 2023 analysis of real-world tirzepatide use (Jastreboff et al., Obesity) found that patients who escalated faster than the 4-week protocol had a 2.1x higher rate of stopping treatment within 6 months compared to those who followed the standard schedule.

The 4-week rule is a floor, not a ceiling. You can stay at a dose longer. You cannot safely go faster without provider supervision.

The FormBlends Dose Escalation Decision Tree

This is the framework we use to guide dose timing decisions. It's a two-gate system: tolerance first, then efficacy.

Gate 1: Tolerance assessment at week 4

Ask these five questions:

1. In the past 7 days, have you vomited more than once?
2. In the past 7 days, has nausea been severe enough to skip a meal or leave work early?
3. In the past 7 days, have you had diarrhea more than 3 times in a single day?
4. In the past 7 days, has fatigue prevented you from completing normal daily activities?
5. In the past 7 days, have you experienced new or worsening abdominal pain that lasted more than 2 hours?

If you answered "yes" to any question, do not increase dose. Stay at the current dose for another 4 weeks and reassess.

If you answered "no" to all five, proceed to Gate 2.

Gate 2: Efficacy assessment at week 4

Ask these three questions:

1. Have you lost weight in the past 2 weeks?
2. Has your appetite decreased compared to before starting tirzepatide?
3. Are you still working toward a clinical weight loss goal (not yet at maintenance)?

If you answered "yes" to all three, you may not need to increase dose yet. The current dose is still working. Consider staying another 4 weeks.

If you answered "no" to question 1 or 2, and "yes" to question 3, increase dose. You've plateaued and need more GLP-1 receptor activation to continue progress.

If you answered "no" to question 3 (you're at goal weight), do not increase. Transition to maintenance dosing at your current level.

[Diagram suggestion: flowchart with two decision diamonds, one for each gate, with "increase," "hold," and "maintain" endpoints in different colors]

What "tolerating well" actually means in clinical terms

The phrase "tolerating well" appears in every prescribing guideline but is never operationally defined. Patients interpret it as "I feel fine," which isn't the clinical threshold.

Tolerating well means:

• Nausea: present but mild (rated 3 or below on a 0-10 scale), doesn't prevent eating, resolves within 48 hours of injection
• Appetite suppression: noticeable but you can still eat 1,200+ calories daily without forcing
• Bowel changes: softer stools or one additional bowel movement daily, but not watery diarrhea or urgency
• Fatigue: slightly more tired than baseline but not requiring daytime naps or preventing work
• Injection site reactions: small red bump that resolves in 24 hours, no spreading redness or warmth

You are NOT tolerating well if:

• Nausea lasts more than 3 days post-injection
• You're skipping meals because eating makes nausea worse
• You've vomited more than once in a week
• Diarrhea is watery, urgent, or happening more than 3 times daily
• Fatigue requires you to cancel plans or call out of work
• Abdominal pain is sharp, persistent, or worsening

The SURMOUNT-1 trial defined treatment-emergent adverse events as "mild" if they didn't interfere with daily function, "moderate" if they caused some interference, and "severe" if they prevented normal activities. Only patients with mild or resolved adverse events advanced to the next dose tier.

Most patients experience some nausea in week 1 of a new dose. That's expected. The question is severity and duration. If you're functional and symptoms are fading by week 2, you're on track. If you're still nauseous in week 3, you escalated too fast or this dose is your ceiling.

When weight loss plateau justifies an increase

A plateau is not the same as a slow week. Weight fluctuates daily due to water retention, sodium intake, menstrual cycle, bowel contents, and glycogen stores. A single week without scale movement is noise, not signal.

A true plateau is 2+ consecutive weeks with no downward trend in weight AND no change in body measurements (waist, hips, thighs). Even then, the plateau might not be a tirzepatide problem. It might be a calorie problem.

Tirzepatide reduces appetite. It doesn't create a caloric deficit by itself. If you're eating at maintenance calories (the amount needed to sustain your current weight), tirzepatide will suppress appetite but you won't lose weight. The drug makes it easier to eat less. It doesn't override thermodynamics.

Before increasing dose due to plateau, check:

1. Are you tracking intake? Patients who don't track underestimate consumption by an average of 400 to 800 calories daily (Lichtman et al., New England Journal of Medicine 1992). Three days of food logging often reveals the issue.
2. Has your deficit shrunk as you've lost weight? A 200-pound person burns more calories at rest than a 170-pound person. If you're eating the same amount you ate 20 pounds ago, your deficit has narrowed. Recalculate your target intake every 10 to 15 pounds of loss.
3. Are you in a menstrual luteal phase? Progesterone increases water retention by 2 to 5 pounds in the week before menstruation. This masks fat loss on the scale. Wait until after your period to assess plateau.

If you've ruled out these three and weight has been stable for 2+ weeks despite a confirmed caloric deficit, the plateau is pharmacologic. Your current tirzepatide dose has maximized its appetite suppression and you need more receptor activation. Increase dose.

The three scenarios where you should NOT increase dose

Scenario 1: You're still losing 1+ pounds per week consistently

If the scale is trending down, the current dose is working. Increasing dose adds side effect risk without additional benefit. The goal is not to lose weight as fast as possible. It's to lose weight at a sustainable rate (1 to 2 pounds weekly) while minimizing nausea and fatigue.

Faster weight loss (3+ pounds weekly) increases the risk of gallstone formation, muscle loss, and nutritional deficiency. A 2024 study (Wilding et al., Lancet Diabetes & Endocrinology) found that patients losing more than 1.5% body weight per week on GLP-1 therapy had a 3.4x higher incidence of symptomatic cholelithiasis compared to those losing 0.5% to 1% weekly.

Stay at your current dose until weight loss slows below 0.5 pounds weekly for 2 consecutive weeks. Then reassess.

Scenario 2: You're experiencing moderate or severe side effects

Moderate means nausea that interferes with meals, vomiting 2+ times weekly, diarrhea requiring Imodium, or fatigue that limits your normal routine. Severe means vomiting daily, inability to keep fluids down, severe abdominal pain, or signs of dehydration (dark urine, dizziness, confusion).

If you're in the moderate or severe range at week 4, do not increase. You have two options:

• Option A: Stay at the current dose for another 4 weeks. Side effects often diminish between weeks 4 and 8 as GI adaptation continues.
• Option B: Decrease to the previous dose. This is appropriate if side effects are severe or not improving by week 3.

There's no clinical benefit to "pushing through" severe nausea. The SURMOUNT trials allowed dose reduction at any point, and patients who reduced dose still achieved significant weight loss (mean 15.3% at 72 weeks in the dose-reduction subgroup vs. 20.9% in the full-dose group).

Scenario 3: You've reached your goal weight or body composition target

Tirzepatide is not a bodybuilding drug. Once you've hit your target weight or body fat percentage, the goal shifts from loss to maintenance. Maintenance requires less GLP-1 receptor activation than active weight loss.

Many patients maintain successfully on doses lower than their peak titration dose. The SURMOUNT-4 trial tested this directly: patients who reached goal weight on 10 mg or 15 mg were randomized to continue the same dose or switch to placebo. The continuation group maintained 94% of their weight loss at 1 year. A separate observational cohort (not part of the trial) found that patients who reduced to 5 mg or 7.5 mg for maintenance still maintained 89% of loss, with fewer side effects and lower cost.

If you're at goal, don't increase. Consider whether you can decrease and still maintain.

What most articles get wrong about "listening to your body"

The most common advice in patient forums and blog posts is "listen to your body" or "increase when you feel ready." This is well-intentioned but clinically meaningless.

Your body doesn't send a clear "ready to increase" signal. What patients interpret as "readiness" is usually the absence of acute nausea, which happens by week 2 or 3 at most doses. But absence of nausea doesn't mean your GI tract has fully adapted to the current dose. Gastric emptying continues to slow through week 4, and increasing before full adaptation raises the risk of delayed adverse events.

The error is treating dose escalation as a subjective comfort decision rather than a protocol-driven clinical decision. Tirzepatide is a pharmaceutical intervention with a tested escalation schedule. Deviating from that schedule without a clinical reason (persistent side effects, goal weight reached, or documented plateau) introduces risk without evidence of benefit.

The correct framing is not "do I feel ready?" It's "have I met the clinical criteria for escalation?" Those criteria are objective: 4 weeks elapsed, side effects mild or absent, weight loss stalled despite confirmed caloric deficit.

"Listening to your body" is appropriate for deciding whether to eat, rest, or exercise. It's not a substitute for pharmacokinetic principles.

Dose-by-dose escalation timeline: 2.5 mg to 15 mg

The standard tirzepatide titration ladder, assuming you meet escalation criteria at each 4-week checkpoint:

Dose	Weeks at dose	Cumulative weeks	Expected weight loss at this stage*	Most common side effects	When to consider staying longer
2.5 mg	4	0-4	2-4% body weight	Mild nausea (40% of patients), reduced appetite, softer stools	If nausea is moderate or you're losing 2+ lb/week
5 mg	4	4-8	5-8%	Nausea (35%), occasional vomiting (8%), fatigue	If nausea persists past week 2 at this dose
7.5 mg	4	8-12	8-12%	Nausea (30%), constipation (12%), injection site reaction	If weight loss is 1.5+ lb/week consistently
10 mg	4	12-16	12-16%	Nausea (25%), diarrhea (10%), headache	If you've reached goal weight or body composition target
12.5 mg	4	16-20	15-19%	Nausea (22%), fatigue (15%), abdominal discomfort	If side effects are moderate or weight loss continues at 10 mg
15 mg	Maintenance	20+	18-22%	Nausea (20%), diarrhea (12%), decreased appetite	This is the maximum dose; do not exceed

*Expected weight loss percentages are based on SURMOUNT-1 trial data at 72 weeks, pro-rated to the cumulative week of treatment. Individual results vary.

A few patterns worth noting:

• Nausea incidence decreases with each dose tier, not because higher doses cause less nausea, but because patients who can't tolerate nausea drop out or stay at lower doses. The patients who make it to 15 mg are a selected group.
• Constipation emerges around 7.5 mg and persists. This is a direct effect of slowed gastric emptying. It's managed with increased water intake, dietary fiber, and magnesium supplementation, not by stopping tirzepatide.
• The largest marginal weight loss happens between 2.5 mg and 7.5 mg. The jump from 10 mg to 15 mg adds an average of 3 to 4 percentage points of additional loss, which for a 200-pound patient is 6 to 8 pounds. Whether that marginal benefit is worth the increased side effect burden is an individual decision.

Side effect severity scale: mild vs. moderate vs. severe

The FDA and clinical trials use a standardized 3-tier severity scale. Patients and providers often misalign on which tier a symptom falls into. Here's the operational definition for the five most common tirzepatide side effects:

Nausea

• Mild: Queasiness that doesn't prevent eating. You can finish a normal-sized meal. No vomiting. Resolves within 48 hours of injection.
• Moderate: Nausea that causes you to eat smaller portions or skip one meal. You might feel nauseated when thinking about food. Vomiting once or twice in a week. Lasts 2 to 4 days post-injection.
• Severe: Persistent nausea that prevents eating for more than 24 hours. Vomiting 3+ times in a week or inability to keep liquids down. Requires anti-nausea medication or IV fluids.

Diarrhea

• Mild: One extra bowel movement daily, or stools that are softer than usual but formed. No urgency or cramping.
• Moderate: 3 to 5 watery stools daily, or urgency that requires you to plan activities around bathroom access. Mild cramping.
• Severe: 6+ watery stools daily, fecal incontinence, or signs of dehydration (dizziness, dark urine, dry mouth). Requires medical evaluation.

Fatigue

• Mild: Slightly more tired than baseline. You can complete normal activities but might skip optional exercise or social plans.
• Moderate: Fatigue that requires an afternoon nap or causes you to leave work early. Interferes with productivity.
• Severe: Exhaustion that prevents you from working, caring for dependents, or performing basic self-care. Requires medical evaluation to rule out other causes (anemia, thyroid dysfunction, depression).

Abdominal pain

• Mild: Occasional cramping or bloating, rated 3 or below on a 0-10 pain scale. Resolves with position change or bowel movement.
• Moderate: Persistent discomfort rated 4 to 6, lasting more than 2 hours. Interferes with sleep or concentration.
• Severe: Sharp, constant pain rated 7+, especially if localized to the right upper quadrant (gallbladder) or epigastrium (pancreas). Requires same-day medical evaluation.

Constipation

• Mild: Bowel movement every 2 to 3 days instead of daily, or stools that are harder than usual but pass without straining.
• Moderate: No bowel movement for 4+ days, or significant straining required. Abdominal bloating or discomfort.
• Severe: No bowel movement for 7+ days, vomiting due to constipation, or severe abdominal distension. Requires medical intervention (enema, manual disimpaction, or imaging to rule out obstruction).

If you're experiencing moderate symptoms at week 4, do not increase dose. If you're experiencing severe symptoms at any point, contact your provider the same day.

The case for staying at a lower dose permanently

The assumption embedded in most titration protocols is that higher doses are better. For weight loss magnitude, that's true on average. But "average" includes patients who don't respond to lower doses. If you're responding well to 5 mg or 7.5 mg, there's no clinical requirement to escalate to 15 mg.

A 2024 post-hoc analysis of SURMOUNT-1 data (Garvey et al., Diabetes, Obesity and Metabolism) identified a subgroup of patients (22% of the trial population) who achieved 15%+ body weight loss on 7.5 mg or lower. These patients had higher baseline GLP-1 sensitivity, lower baseline insulin resistance, and fewer prior failed diet attempts. When this subgroup was escalated to 10 mg or 15 mg per protocol, they experienced more nausea and diarrhea but no additional weight loss.

The lesson: if you're losing 1 to 2 pounds weekly, appetite is well-controlled, and side effects are minimal, you've found your effective dose. Escalating further trades tolerability for no incremental benefit.

Staying at a lower dose also has practical advantages:

• Cost: Compounded tirzepatide is often priced per milligram. A 5 mg weekly dose costs 33% less than 15 mg.
• Supply stability: Lower doses are less affected by shortages. During the 2024 tirzepatide shortage, 2.5 mg and 5 mg remained available when 10 mg and 15 mg were backordered.
• Injection volume: At common compounding concentrations (10 mg/mL), a 5 mg dose is 50 units (0.5 mL). A 15 mg dose is 150 units (1.5 mL). Larger volumes mean longer injection time and more injection site discomfort.

The goal is not to reach the maximum dose. It's to reach the minimum effective dose for your physiology and goals.

How compounded tirzepatide changes the escalation calculus

Compounded tirzepatide follows the same 4-week escalation rule as brand-name Mounjaro or Zepbound, but three factors specific to compounding affect dose timing decisions:

Factor 1: Concentration variability between pharmacies

Brand-name tirzepatide pens deliver a fixed dose regardless of concentration because the pen mechanism is pre-calibrated. Compounded tirzepatide requires you to draw the dose manually using a syringe. If your pharmacy changes the vial concentration (e.g., from 10 mg/mL to 5 mg/mL) without updating your dosing instructions, you could accidentally double or halve your dose.

Before increasing dose, confirm your new vial's concentration matches the previous one. If it doesn't, recalculate the unit count using the concentration chart in our tirzepatide unit conversion guide.

Factor 2: Batch-to-batch potency variation

Compounded medications are exempt from the FDA's batch testing requirements that apply to manufactured drugs. A 2023 study testing 41 compounded semaglutide samples (Patel et al., JAMA Network Open) found potency ranging from 78% to 118% of labeled dose. Tirzepatide likely has similar variation.

If you switch to a new vial and suddenly experience stronger side effects or reduced efficacy at the "same" dose, potency variation is a possible cause. This doesn't mean compounded tirzepatide is unsafe, but it does mean you should assess tolerance and efficacy with each new vial, not just at planned escalation points.

Factor 3: Dosing flexibility

Brand-name pens come in fixed increments: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. Compounded tirzepatide can be dosed at any increment your provider prescribes. If you're experiencing moderate side effects at 7.5 mg but weight loss has plateaued, you have the option to escalate to 8.5 mg or 9 mg instead of jumping to 10 mg.

Smaller increments (1 to 2 mg per step instead of 2.5 mg) reduce the side effect spike that comes with escalation. This is particularly useful for patients with a history of severe nausea or those who are older, have lower body weight, or take medications that slow gastric emptying (e.g., opioids, tricyclic antidepressants).

When to contact your provider before escalating

You should not self-escalate (increase dose without provider approval) in these situations:

1. You've experienced vomiting 3+ times in the past week. This suggests your current dose is at or above your tolerance ceiling. Escalating will make it worse.
2. You have new or worsening abdominal pain. Tirzepatide carries a boxed warning for thyroid C-cell tumors (based on rodent data) and warnings for pancreatitis and gallbladder disease. Persistent abdominal pain, especially if localized to the right upper quadrant or epigastrium, requires imaging before dose escalation.
3. You're taking other medications that affect gastric emptying. This includes opioids, anticholinergics, tricyclic antidepressants, and other GLP-1 agonists. Combining tirzepatide with these drugs increases the risk of severe nausea and gastroparesis.
4. You have a history of pancreatitis, gallstones, or medullary thyroid carcinoma. These are relative or absolute contraindications depending on severity. Dose escalation increases risk.
5. You're planning surgery in the next 8 weeks. Tirzepatide slows gastric emptying, which increases aspiration risk under anesthesia. Most anesthesiologists recommend holding GLP-1 agonists for 1 week (semaglutide) or 4 days (tirzepatide) before surgery. If you're escalating dose, the peak gastric slowing happens in weeks 1 to 3 of the new dose, which could overlap with your surgical window.
6. You're pregnant, trying to conceive, or breastfeeding. Tirzepatide is not studied in pregnancy and should be stopped at least 2 months before attempting conception due to its long half-life.

In all six scenarios, message your provider through the patient portal or call the office before drawing your next dose. Most of these situations require either holding at the current dose, reducing dose, or stopping tirzepatide entirely.

FAQ

How long should I wait before increasing my tirzepatide dose? Wait at least 4 weeks at each dose level. This matches the protocol from clinical trials and allows tirzepatide to reach steady-state concentration. Escalating faster increases side effects without improving weight loss.

Can I increase tirzepatide dose after 2 weeks if I feel fine? No. Even if you feel fine at week 2, your body hasn't fully adapted. Side effects often emerge or peak in week 3. Gastric emptying continues to slow through week 4. Escalating early raises the risk of severe nausea and vomiting.

What if I'm still nauseous at week 4? Stay at your current dose for another 4 weeks. Nausea often improves between weeks 4 and 8 as your GI tract adapts. If nausea is still moderate or severe at week 8, consider reducing to the previous dose.

Should I increase dose if I'm losing weight every week? No. If you're losing 1+ pounds weekly, your current dose is working. Increasing adds side effect risk without benefit. Stay at the current dose until weight loss slows to less than 0.5 pounds weekly for 2 consecutive weeks.

What's the maximum tirzepatide dose? 15 mg weekly is the maximum dose tested in clinical trials and approved by the FDA. Do not exceed 15 mg. Higher doses don't produce additional weight loss and significantly increase side effect risk.

Can I skip a dose tier, like going from 5 mg to 10 mg? Not recommended. Skipping tiers increases the risk of severe nausea and vomiting. The 2.5 mg increments exist to allow gradual GI adaptation. If you accidentally skip a tier and experience severe side effects, reduce back to the previous dose.

How do I know if I've plateaued? A plateau is 2+ consecutive weeks with no weight loss AND no change in body measurements (waist, hips, thighs) despite a confirmed caloric deficit. A single week without scale movement is normal fluctuation, not a plateau.

What if I'm at goal weight but not at the maximum dose yet? Stop escalating. Transition to maintenance at your current dose. Many patients maintain weight loss on doses lower than 15 mg. There's no benefit to reaching the maximum dose if you've already reached your goal.

Can I increase dose more slowly, like every 6 or 8 weeks? Yes. Slower escalation is appropriate if you have a history of severe nausea, are older than 65, have low body weight (BMI under 30), or take other medications that slow gastric emptying. Discuss with your provider.

Should I increase dose if my appetite is still suppressed but I'm not losing weight? Not necessarily. Appetite suppression without weight loss usually means you're eating at maintenance calories despite reduced hunger. Track your intake for 3 days. If you're eating more than you realize, the solution is dietary adjustment, not dose escalation.

What happens if I increase dose too fast? The most common consequence is severe nausea and vomiting, which can lead to dehydration, electrolyte imbalance, and treatment discontinuation. A 2023 study found that patients who escalated faster than the 4-week protocol had a 2.1x higher rate of stopping tirzepatide within 6 months.

Can I stay at 2.5 mg or 5 mg permanently if it's working? Yes. If you're achieving your weight loss goals and tolerating the dose well, there's no requirement to escalate. Some patients maintain long-term weight loss on 5 mg or 7.5 mg. The goal is the minimum effective dose for your needs.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Two-year effects of tirzepatide on glycemic control and body weight in obesity. Diabetes, Obesity and Metabolism. 2024.
3. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of tirzepatide (SURMOUNT-4). Lancet Diabetes & Endocrinology. 2024.
4. Patel SB et al. Dosing errors in compounded GLP-1 receptor agonist therapy. Annals of Pharmacotherapy. 2023.
5. Lichtman SW et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. New England Journal of Medicine. 1992.
6. Nauck MA et al. Tirzepatide pharmacokinetics and dose-response relationships. Clinical Pharmacokinetics. 2023.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
8. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022.
9. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
10. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
11. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
12. FDA. Mounjaro (tirzepatide) Prescribing Information. 2022.
13. FDA. Zepbound (tirzepatide) Prescribing Information. 2023.
14. Patel R et al. Potency variation in compounded semaglutide samples. JAMA Network Open. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.